{
  "metrics": {
    "totalTests": 10,
    "correctDecisions": 6,
    "accuracy": 0.6,
    "consistencyRate": 0.7,
    "jsonValidRate": 1,
    "avgConfidence": 0.9475,
    "needReviewRate": 0.3,
    "confusionMatrix": {
      "truePositive": 2,
      "falsePositive": 0,
      "trueNegative": 4,
      "falseNegative": 1,
      "uncertain": 0
    }
  },
  "results": [
    {
      "literatureId": "test-001",
      "title": "Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial",
      "expectedDecision": "include",
      "actualDecision": "exclude",
      "isCorrect": false,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.925,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "we randomly assigned 800 adults with type 2 diabetes",
          "I": "Efficacy and Safety of Empagliflozin in Patients with Type 2 Diabetes",
          "C": "placebo-controlled trial",
          "S": "randomized, double-blind, placebo-controlled trial"
        },
        "conclusion": "exclude",
        "confidence": 0.9,
        "reason": "虽然该文献在PICO标准上完全匹配（研究人群为2型糖尿病成人患者，干预措施为SGLT2抑制剂empagliflozin，对照为安慰剂，研究设计为RCT），且满足纳入标准中的年龄、研究设计、干预措施、发表语言和时间要求，但文献明确显示其主要终点为血糖控制指标（HbA1c变化），而非方案要求的心血管结局（主要不良心血管事件、心衰住院、心血管死亡）。摘要中仅提及次要终点包括体重、血压和不良事件，未报告任何心血管结局数据，因此不符合纳入标准第4条'报告心血管结局数据'的要求，应予排除。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "patients with type 2 diabetes and inadequate glycemic control (HbA1c 7.0-10.0%)",
          "I": "to receive empagliflozin 10 mg, empagliflozin 25 mg, or placebo once daily",
          "C": "placebo once daily",
          "S": "randomized, double-blind, placebo-controlled trial"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "尽管该研究符合PICO中的P、I、C和S标准，且为RCT设计，但其主要结局为HbA1c变化、体重和血压等代谢指标，并未报告任何心血管结局（如MACE、心衰住院或心血管死亡）。根据纳入标准第4条，必须报告心血管结局数据方可纳入，而摘要中无相关信息支持此关键结局，因此排除。"
      },
      "processingTime": 12188
    },
    {
      "literatureId": "test-002",
      "title": "Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes",
      "expectedDecision": "include",
      "actualDecision": "include",
      "isCorrect": true,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "8246 patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease",
          "I": "ertugliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor",
          "C": "ertugliflozin (5 mg or 15 mg) or placebo, in addition to standard care",
          "S": "We randomly assigned 8246 patients"
        },
        "conclusion": "include",
        "confidence": 0.95,
        "reason": "该文献完全符合纳入标准：研究对象为2型糖尿病成人患者且合并动脉粥样硬化性心血管疾病；干预措施为SGLT2抑制剂（ertugliflozin）；对照为安慰剂加标准治疗；研究设计为随机对照试验；报告了主要不良心血管事件和心衰住院等心血管结局；发表于2010年后且为英文文献。同时未触发任何排除标准，研究设计严谨，证据充分，应纳入系统综述。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease",
          "I": "receive ertugliflozin (5 mg or 15 mg)",
          "C": "placebo, in addition to standard care",
          "S": "We randomly assigned 8246 patients... to receive ertugliflozin... or placebo"
        },
        "conclusion": "include",
        "confidence": 0.95,
        "reason": "该研究纳入2型糖尿病成人患者，使用SGLT2抑制剂ertugliflozin作为干预，对照为安慰剂加标准治疗，报告了主要不良心血管事件等结局，且为随机对照试验设计。完全符合PICO标准和纳入标准。未触发任何排除标准，信息充分，设计严谨，故决定纳入。"
      },
      "processingTime": 11237
    },
    {
      "literatureId": "test-003",
      "title": "Systematic Review and Meta-Analysis of SGLT2 Inhibitors in Type 2 Diabetes: A Comprehensive Assessment",
      "expectedDecision": "exclude",
      "actualDecision": "exclude",
      "isCorrect": true,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "partial",
          "S": "mismatch"
        },
        "evidence": {
          "P": "in adults with type 2 diabetes",
          "I": "SGLT2 inhibitors",
          "C": "comparing SGLT2 inhibitors with placebo or active comparators",
          "S": "Systematic Review and Meta-Analysis"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献明确为系统评价和Meta分析，研究设计为二次研究而非原始随机对照试验，直接触发排除标准第1条（排除综述、系统评价、Meta分析）。虽然P（2型糖尿病成人患者）和I（SGLT2抑制剂）完全匹配，C（安慰剂或常规降糖疗法）部分匹配（提及与安慰剂或活性对照比较），但研究设计不匹配且触发排除标准，因此必须排除。该文献发表于2010年后且为英文，但研究设计类型不符合纳入要求。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "partial",
          "S": "mismatch"
        },
        "evidence": {
          "P": "We included randomized controlled trials comparing SGLT2 inhibitors with placebo or active comparators in adults with type 2 diabetes.",
          "I": "We included randomized controlled trials comparing SGLT2 inhibitors with placebo or active comparators in adults with type 2 diabetes.",
          "C": "comparing SGLT2 inhibitors with placebo or active comparators",
          "S": "We included randomized controlled trials comparing SGLT2 inhibitors with placebo or active comparators in adults with type 2 diabetes."
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献为系统综述和Meta分析，尽管其纳入的研究符合PICO中的P、I和部分C标准，且研究人群为成人2型糖尿病患者，干预措施为SGLT2抑制剂，对照包括安慰剂或常规疗法，结局包含心血管事件，但本文本身并非原始RCT研究，而是对RCT的汇总分析，因此研究设计不符合方案要求的原始随机对照试验(S)，触发排除标准中‘系统评价、Meta分析’的排除条件，故应排除。"
      },
      "processingTime": 15737
    },
    {
      "literatureId": "test-004",
      "title": "Dapagliflozin Improves Cardiac Function in Diabetic Rats: An Experimental Study",
      "expectedDecision": "exclude",
      "actualDecision": "exclude",
      "isCorrect": true,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "mismatch",
          "I": "match",
          "C": "partial",
          "S": "mismatch"
        },
        "evidence": {
          "P": "Diabetes was induced in male Sprague-Dawley rats by streptozotocin injection",
          "I": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day)",
          "C": "vehicle for 8 weeks",
          "S": "diabetic rats"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献明确不符合纳入标准，主要问题在于：(1)研究对象为糖尿病大鼠而非人类2型糖尿病患者，违反了PICO中P标准；(2)研究设计为动物实验而非随机对照试验，违反了S标准；(3)对照为vehicle而非安慰剂或常规降糖疗法，仅部分匹配C标准。虽然干预措施为SGLT2抑制剂（dapagliflozin）匹配I标准，但由于研究对象为动物且研究设计不符合RCT要求，触发了排除标准中的'动物实验或体外实验'条款，因此必须排除。该文献为明确的动物实验研究，证据充分，排除决策高度可靠。"
      },
      "qwenResult": {
        "judgment": {
          "P": "mismatch",
          "I": "match",
          "C": "partial",
          "S": "mismatch"
        },
        "evidence": {
          "P": "Diabetes was induced in male Sprague-Dawley rats by streptozotocin injection.",
          "I": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks.",
          "C": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks.",
          "S": "Rats were randomly assigned to receive dapagliflozin (1 mg/kg/day) or vehicle for 8 weeks."
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该研究在糖尿病大鼠模型中进行，研究人群为动物而非2型糖尿病成人患者，不符合P标准。尽管干预措施为dapagliflozin且采用随机分组，但属于动物实验，研究设计不符合RCT的人群范畴。根据排除标准第3条，动物实验应被排除。虽然方法提及随机分配，但整体研究不适用于人类患者，无法提供关于心血管结局的临床证据，因此最终决定排除。"
      },
      "processingTime": 12670
    },
    {
      "literatureId": "test-005",
      "title": "Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy",
      "expectedDecision": "include",
      "actualDecision": "include",
      "isCorrect": true,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "we randomly assigned 4401 participants with type 2 diabetes and albuminuric chronic kidney disease",
          "I": "to receive canagliflozin at a dose of 100 mg daily",
          "C": "or placebo",
          "S": "In this double-blind trial, we randomly assigned 4401 participants"
        },
        "conclusion": "include",
        "confidence": 0.95,
        "reason": "该文献完全符合纳入标准：研究人群为2型糖尿病成人患者（P匹配），干预措施为SGLT2抑制剂canagliflozin（I匹配），对照为安慰剂（C匹配），研究设计为随机双盲对照试验（S匹配）。文献发表于2010年后且为英文，报告了心血管结局数据（摘要中明确提到'cardiovascular events'）。该研究未触发任何排除标准，是一项高质量的心血管结局RCT研究，应纳入系统综述。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "participants with type 2 diabetes and albuminuric chronic kidney disease",
          "I": "canagliflozin at a dose of 100 mg daily",
          "C": "placebo",
          "S": "In this double-blind trial, we randomly assigned 4401 participants...to receive canagliflozin...or placebo"
        },
        "conclusion": "include",
        "confidence": 0.95,
        "reason": "该研究为RCT，纳入成人2型糖尿病患者，干预措施为SGLT2抑制剂（canagliflozin），对照为安慰剂，报告了心血管事件作为复合终点的一部分。完全符合PICO标准和纳入标准。尽管主要结局是肾脏相关复合终点，但明确提及‘death from renal or cardiovascular causes’，说明心血管结局数据被报告，满足方案要求。无排除标准触发项。"
      },
      "processingTime": 11345
    },
    {
      "literatureId": "test-006",
      "title": "Real-World Experience with SGLT2 Inhibitors: A Retrospective Cohort Study",
      "expectedDecision": "exclude",
      "actualDecision": "exclude",
      "isCorrect": true,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "mismatch",
          "S": "mismatch"
        },
        "evidence": {
          "P": "\"12,543 adults with type 2 diabetes\"",
          "I": "\"patients with type 2 diabetes who initiated SGLT2 inhibitor therapy\"",
          "C": "摘要中未提及安慰剂或常规降糖疗法作为对照",
          "S": "\"We conducted a retrospective cohort study\""
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献明确触发排除标准，应予以排除。具体原因：(1)研究设计为回顾性队列研究，明确不符合PICO标准中要求的随机对照试验(RCT)，且触发排除标准第7条(观察性研究)；(2)研究人群和干预措施符合PICO标准，但缺乏明确的对照组设置，未提及安慰剂或常规降糖疗法；(3)研究结局指标为HbA1c、体重、血压变化及安全性事件，而非方案要求的心血管结局(主要不良心血管事件、心衰住院、心血管死亡)。这是一项真实世界研究，而非随机对照试验，因此不符合纳入条件。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "mismatch",
          "S": "mismatch"
        },
        "evidence": {
          "P": "We identified 12,543 adults with type 2 diabetes who initiated SGLT2 inhibitor therapy between 2014 and 2020.",
          "I": "We identified 12,543 adults with type 2 diabetes who initiated SGLT2 inhibitor therapy between 2014 and 2020.",
          "C": "Methods: We conducted a retrospective cohort study using electronic health records from a large healthcare system.",
          "S": "Methods: We conducted a retrospective cohort study using electronic health records from a large healthcare system."
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该研究为回顾性队列研究，不符合方案要求的随机对照试验（RCT）设计，因此S维度不匹配。尽管研究人群（P）为成人2型糖尿病患者且干预措施（I）为SGLT2抑制剂，符合纳入标准，但对照（C）未明确使用安慰剂或常规降糖疗法，且研究设计属于观察性研究，触发排除标准第7条。因此，尽管报告了相关结局，仍应排除。"
      },
      "processingTime": 12213
    },
    {
      "literatureId": "test-007",
      "title": "Pharmacokinetics and Pharmacodynamics of Empagliflozin in Healthy Volunteers",
      "expectedDecision": "exclude",
      "actualDecision": "pending",
      "isCorrect": false,
      "hasConsensus": false,
      "needReview": true,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "mismatch",
          "I": "partial",
          "C": "match",
          "S": "partial"
        },
        "evidence": {
          "P": "In this Phase 1 study, we evaluated the pharmacokinetics and pharmacodynamics of empagliflozin in 48 healthy male volunteers",
          "I": "Participants received single oral doses of empagliflozin (1, 5, 10, 25, 50, or 100 mg) in a randomized, placebo-controlled, double-blind manner",
          "C": "in a randomized, placebo-controlled, double-blind manner",
          "S": "In this Phase 1 study...in a randomized, placebo-controlled, double-blind manner"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献明确不符合纳入标准，主要问题在于：(1)研究人群为健康志愿者而非2型糖尿病患者，与PICO标准中的P维度完全不匹配；(2)虽然干预措施使用了SGLT2抑制剂empagliflozin，但这是一项药代动力学研究而非疗效研究，且为单次给药；(3)研究设计为I期临床试验，主要关注药代动力学参数，而非心血管结局；(4)触发了排除标准中的'健康志愿者研究'和'未报告心血管结局数据'。因此，该文献应被排除。"
      },
      "qwenResult": {
        "judgment": {
          "P": "mismatch",
          "I": "match",
          "C": "match",
          "S": "partial"
        },
        "evidence": {
          "P": "In this Phase 1 study, we evaluated the pharmacokinetics and pharmacodynamics of empagliflozin in 48 healthy male volunteers.",
          "I": "Participants received single oral doses of empagliflozin (1, 5, 10, 25, 50, or 100 mg) in a randomized, placebo-controlled, double-blind manner.",
          "C": "Participants received single oral doses of empagliflozin (1, 5, 10, 25, 50, or 100 mg) in a randomized, placebo-controlled, double-blind manner.",
          "S": "In this Phase 1 study, we evaluated the pharmacokinetics and pharmacodynamics of empagliflozin in 48 healthy male volunteers."
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该研究纳入的是健康志愿者，不符合P（2型糖尿病成人患者）的标准，明确触发排除标准中的‘健康志愿者研究’。尽管干预措施为SGLT2抑制剂且采用RCT设计，对照为安慰剂，但研究人群不匹配是关键缺陷。此外，该研究为Phase 1药代动力学试验，主要目的并非评估心血管结局，也未报告相关数据，因此不满足O和S的完整要求。综合判断应排除。"
      },
      "processingTime": 13333
    },
    {
      "literatureId": "test-008",
      "title": "Comparative Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors in Elderly Patients with Type 2 Diabetes",
      "expectedDecision": "exclude",
      "actualDecision": "pending",
      "isCorrect": false,
      "hasConsensus": false,
      "needReview": true,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "partial",
          "S": "mismatch"
        },
        "evidence": {
          "P": "Medicare beneficiaries aged ≥65 years with type 2 diabetes",
          "I": "patients initiating SGLT2 inhibitors",
          "C": "compared with those initiating DPP-4 inhibitors",
          "S": "We conducted a nationwide cohort study"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献明确触发排除标准，应予以排除。虽然研究人群(P)为2型糖尿病成人患者，干预措施(I)为SGLT2抑制剂，均符合纳入标准；对照(C)为DPP-4抑制剂而非安慰剂或常规降糖疗法，属于部分匹配；但最关键的是研究设计(S)为队列研究而非随机对照试验，明确不符合PICO标准中的RCT要求，且触发排除标准第7条'观察性研究（队列、病例对照）'。该研究使用医疗保险索赔数据进行回顾性队列分析，缺乏随机化设计，因此不符合系统综述的纳入条件。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "mismatch",
          "S": "mismatch"
        },
        "evidence": {
          "P": "We conducted a nationwide cohort study using claims data from Medicare beneficiaries aged ≥65 years with type 2 diabetes.",
          "I": "We compared patients initiating SGLT2 inhibitors (n=42,371) with those initiating DPP-4 inhibitors (n=126,806) between 2013 and 2017.",
          "C": "those initiating DPP-4 inhibitors (n=126,806)",
          "S": "We conducted a nationwide cohort study using claims data from Medicare beneficiaries"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该研究为队列研究，不符合方案要求的随机对照试验（RCT）设计，故S维度不匹配。尽管研究人群为2型糖尿病成人患者（P匹配），干预措施为SGLT2抑制剂（I匹配），但对照为DPP-4抑制剂而非安慰剂或常规降糖疗法（C不匹配）。此外，研究设计属于观察性研究，明确触发排除标准第7条。因此，尽管报告了心血管结局，仍应排除。"
      },
      "processingTime": 12025
    },
    {
      "literatureId": "test-009",
      "title": "Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report",
      "expectedDecision": "exclude",
      "actualDecision": "exclude",
      "isCorrect": true,
      "hasConsensus": true,
      "needReview": false,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "mismatch",
          "S": "mismatch"
        },
        "evidence": {
          "P": "\"A 52-year-old man with type 2 diabetes\"",
          "I": "\"patient treated with dapagliflozin\"",
          "C": "摘要中未提及安慰剂或常规降糖疗法对照",
          "S": "\"Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report\"，摘要中明确描述为病例报告"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献明确触发排除标准，应予以排除。理由如下：(1)研究设计为病例报告（标题和摘要中明确标注），属于排除标准第2项；(2)虽然研究人群（2型糖尿病患者）和干预措施（SGLT2抑制剂）符合PICO标准，但缺乏对照组，且未报告心血管结局数据；(3)病例报告主要关注SGLT2抑制剂相关的酮症酸中毒不良事件，而非心血管结局，与研究方案的核心结局指标不符。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "mismatch",
          "S": "mismatch"
        },
        "evidence": {
          "P": "A 52-year-old man with type 2 diabetes on dapagliflozin 10 mg daily presented to the emergency department with nausea, vomiting, and abdominal pain.",
          "I": "A 52-year-old man with type 2 diabetes on dapagliflozin 10 mg daily presented to the emergency department with nausea, vomiting, and abdominal pain.",
          "C": "There is no mention of a control group or comparison with placebo or conventional therapy.",
          "S": "This is a case report, as indicated by the title: 'Severe Diabetic Ketoacidosis Associated with SGLT2 Inhibitor Use: A Case Report'."
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献为病例报告，研究设计不符合方案要求的随机对照试验（RCT），且未设置对照组，无法满足C和S维度的要求。虽然研究对象为2型糖尿病成人患者并使用SGLT2抑制剂，符合P和I标准，但因研究设计属于排除标准第2条明确列出的‘病例报告’，故应排除。本研究旨在描述单一不良事件，不提供关于心血管结局的群体层面证据。"
      },
      "processingTime": 11897
    },
    {
      "literatureId": "test-010",
      "title": "Effect of Sotagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Moderate Renal Impairment",
      "expectedDecision": "uncertain",
      "actualDecision": "pending",
      "isCorrect": false,
      "hasConsensus": false,
      "needReview": true,
      "avgConfidence": 0.95,
      "deepseekResult": {
        "judgment": {
          "P": "match",
          "I": "mismatch",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "we enrolled 10,584 patients with type 2 diabetes",
          "I": "sotagliflozin, a dual SGLT1 and SGLT2 inhibitor",
          "C": "randomly assigned to receive sotagliflozin 200 mg or placebo",
          "S": "In this randomized, double-blind, placebo-controlled trial"
        },
        "conclusion": "exclude",
        "confidence": 0.95,
        "reason": "该文献虽然符合研究人群（2型糖尿病患者）、对照（安慰剂）和研究设计（随机对照试验）标准，但干预措施不符合要求。文献研究的是sotagliflozin，这是一种双重SGLT1和SGLT2抑制剂，而非方案要求的纯SGLT2抑制剂（如empagliflozin、dapagliflozin、canagliflozin等）。由于干预措施类型不匹配，且该药物作用机制与纯SGLT2抑制剂存在差异，因此决定排除。文献发表于2010年后，报告了心血管结局数据，但干预措施的不匹配是排除的主要原因。"
      },
      "qwenResult": {
        "judgment": {
          "P": "match",
          "I": "match",
          "C": "match",
          "S": "match"
        },
        "evidence": {
          "P": "patients with type 2 diabetes, cardiovascular disease, and an estimated glomerular filtration rate of 25 to 60 ml per minute per 1.73 m²",
          "I": "sotagliflozin, a dual SGLT1 and SGLT2 inhibitor",
          "C": "randomly assigned to receive sotagliflozin 200 mg or placebo once daily",
          "S": "randomized, double-blind, placebo-controlled trial"
        },
        "conclusion": "include",
        "confidence": 0.95,
        "reason": "该研究纳入成人2型糖尿病患者，符合P标准；干预措施为SGLT2抑制剂（sotagliflozin），尽管其同时抑制SGLT1，但明确包含SGLT2抑制作用，符合I标准；对照为安慰剂，符合C标准；研究设计为RCT，符合S标准。研究报告了心血管死亡、心衰住院等主要心血管结局，满足结局指标要求。所有纳入标准均满足，且未触发任何排除标准，因此决定纳入。"
      },
      "processingTime": 12769
    }
  ]
}